COMMUNIQUÉS West-GlobeNewswire

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
21/03/2025
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal [...]
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
21/03/2025
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
21/03/2025
FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked [...]
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
21/03/2025
Additional approximately $21 million tied to data release for the Company’s BEST1 program RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a [...]
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
21/03/2025
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
21/03/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 21 March 2025 at 15.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
21/03/2025
Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic [...]
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
21/03/2025
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
21/03/2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
TOMI Environmental Solutions Expands into Aquaculture with New Partner, Algafeed
21/03/2025
FREDERICK, Md., March 21, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, is pleased to announce the [...]
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
21/03/2025
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today [...]
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
21/03/2025
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company") , a biopharmaceutical company specializing in [...]
Vireo Growth Inc. Files Definitive Information Circular and Provides Merger Transaction Updates
21/03/2025
– Filing of Definitive Information Circular and receipt of shareholder approval mark key milestones in closing process – – Missouri, Nevada and Utah transactions on track to close during the second quarter of 2025 – [...]
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
21/03/2025
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME [...]
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
21/03/2025
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris ® or the Company [...]
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030
21/03/2025
ORION CORPORATION PRESS RELEASE 21 MARCH 2025 at 13:00 EET Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, pharmaceutical companies invested more than [...]
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
21/03/2025
BOSTON and SAN DIEGO, March 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Conavi Medical Corp. Announces Upsize to its Previously Announced Public Offering
21/03/2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi ” or the “ Company ”), a [...]
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
21/03/2025
Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 data Full dataset to be [...]

Pages